Post

Lilly agrees to buy POINT Biopharma for $1.4bn

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of radiopharmaceutical company POINT …

WHO’s SAGE recommends Takeda’s dengue vaccine

The World Health Organisation’s (WHO) Strategic Advisory Group of Experts (SAGE) has recommended Takeda’s QDENGA (dengue tetravalent vaccine [live, attenuated]) …

Nitric oxide by NOxy Health Products for Diabetic Foot Ulcers: Likelihood of Approval

Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers. According …

Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval

Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor. …

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase …